May 14th 2024
During a Case-Based Roundtable® event, Jonathan L. Kaufman, MD, discussed which lines of therapy and at what doses would be appropriate to use selinexor in a patient with relapsed/refractory multiple myeloma in the second article of a 2-part series.
Community Practice Connections™: Real-World Applications of Novel Therapies Across TNBC and Addressing Disparities in Care
View More
6th Annual Precision Medicine Symposium: An Illustrated Tumor Board
October 18-19, 2024
Register Now!
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Phase III Study With Venetoclax Combo Identifies New Biomarker for Relapsed/Refractory Myeloma
December 12th 2019The phase III BELLINI trial demonstrated translocation 11;14 and high BCL2 gene expression are predictive of response to treatment with the addition of venetoclax to bortezomib plus dexamethasone in patients with relapsed/refractory multiple myeloma, according to the findings presented at the 2019 ASH Annual Meeting.
Read More
Daratumumab Leads to PFS Improvement in Patients With Transplant-Ineligible Myeloma
December 11th 2019A significant proportion of patients with transplant-ineligible newly diagnosed multiple myeloma alive and progression free after >3 years following treatment with daratumumab in addition to standard first-line therapy, according to updated safety and efficacy findings from the randomized ALCYONE study.
Read More
Impressive Results Continue With Updated Data on bb21217 in Multiple Myeloma
December 11th 2019In the phase I CRB-402 study, patients with heavily pretreated relapsed/refractory multiple myeloma and minimal residual disease negativity had very good partial responses to the anti-BCMA CAR T cell therapy bb21217, according to updated results presented at the 2019 American Society of Hematology Annual Meeting.<br />
Read More
Landgren Details Pros and Cons of Multiple Myeloma Regimens in Treatment-Naive Setting
December 10th 2019 In a <em>Targeted Oncology </em>case-based peer perspectives live discussion with a group of physicians, C. Ola Landgren, MD, PhD, reviewed several combination regimens used in the treatment of multiple myeloma. Landgren, chief of the Myeloma Service at Memorial Sloan Kettering Cancer Center in New York, used the case of a 51-year-old man with standard-risk disease to highlight the benefits and drawbacks of each therapy strategy.
Read More
GRIFFIN Follow-Up Shows Promising Responses With Daratumumab plus VRD
December 10th 2019Updated results of the GRIFFIN trial revealed that the addition of daratumumab to a standard-of-care regimen used in the treatment of newly diagnosed multiple myeloma met the trials primary end point of higher rates of stringent complete response in patients who are eligible for transplant.
Read More
Safety Run-In Cohort Supports Addition of Isatuximab to Chemotherapy Triplet in Myeloma
December 10th 2019In an interview with Targeted Oncology, Katja Weisel, MD, discussed the safety findings of the 4-drug chemotherapy regimen in the GMMG-CONCEPT trial, which were presented at the 17<sup>th</sup> International Myeloma Workshop.
Read More
Daratumumab/Carfilzomib Prolongs PFS in Patients With R/R Myeloma
December 10th 2019In the phase III CANDOR trial, the addition of daratumumab to carfilzomib and dexamethasone reduced the risk of disease progression or death by 37% compared with carfilzomib and dexamethasone alone in patients with relapsed/refractory multiple myeloma, according to findings from the phase III CANDOR trial presented at the 2019<br /> American Society of Hematology Annual Meeting.
Read More
Encouraging signs of dose-dependent efficacy, as well as a promising safety profile, were observed in patients with heavily pretreated relapsed/refractory multiple myeloma who were treated with CC-93269, a human IgG1-based T-cell engager that binds to BCMA and CD3 epsilon in a 2+1 format.
Read More
CAR T-Cell Therapy Targeting BCMA and CD38 Induces Positive Responses in Multiple Myeloma
December 8th 2019Patients with a difficult-to-treat form of multiple myeloma who were treated with a novel, bispecific anti-BCMA/anti-CD38 chimeric antigen receptor (CAR) T-cell therapy experienced promising responses and a manageable safety profile, according to results of a study that were presented at the 61st Annual American Society of Hematology Annual Meeting and Exposition.<br />
Read More
Genomic Features Associated With Higher Risk of Progression in Smoldering Myeloma
December 7th 2019In an interview with Targeted Oncology, Mark W. Bustoros, MD, discussed the findings from the study evaluating the genomic predictors of progression in patients with SMM and how these findings will impact treatment decisions for these patients in the future.
Read More